Loading
NASDAQFinancial ServicesAsset Management
Latest quote
$2.38
−$0.16 · -6.30%
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.
Latest quote
$2.38
−$0.16 · -6.30%
Regular session · ET · Market data may be delayed.
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.
Day range
Current $2.38
52-week range
Current $2.38
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
58
Fair Value
Sentiment
63
Bullish
Risk
72
High Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.
Day range
Current $2.38
52-week range
Current $2.38
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.02M USD | 520K USD | 644K USD | 787K USD | 522K USD |
| Cost of goods sold | 500K USD | 582K USD | 583K USD | 463K USD | 298K USD |
| Gross profit | 5.52M USD | −62K USD | 61K USD | 324K USD | 224K USD |
| Research and development | 3.51M USD | 3.66M USD | 2.94M USD | 4.26M USD | 5.99M USD |
| Selling, general, and administrative | 23.13M USD | 10.12M USD | 9.27M USD | 10.64M USD | 12.18M USD |
| Operating expenses | 26.64M USD | 13.84M USD | 12.49M USD | 15.84M USD | 18.37M USD |
| Interest income | — | — | 257K USD | — | — |
| Interest expense | 635K USD | 17K USD | — | 834K USD | — |
| Depreciation and amortization | 680K USD | 60K USD | 162K USD | 255K USD | 312K USD |
| Operating income | −21.12M USD | −13.9M USD | −12.43M USD | −15.52M USD | −18.14M USD |
| Net income | −40.89M USD | −11.74M USD | −8.85M USD | −14.07M USD | −18.13M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 1, 2025 | 1:50 | — | — |
Stock split | May 2, 2025 | 1:15 | — | — |
Stock split | Aug 17, 2023 | 1:50 | — | — |
Stock split | Jan 4, 2021 | 1:35 | — | — |
Stock split | Jan 23, 2018 | 1:5 | — | — |
Effective Jul 1, 2025
1:50
Effective May 2, 2025
1:15
Effective Aug 17, 2023
1:50
Effective Jan 4, 2021
1:35
Effective Jan 23, 2018
1:5
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
